NEW YORK, Jan. 27, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of XBiotech Inc. (“XBiotech”) (Nasdaq:XBIT) between April 15, 2015 and November 23, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Western District of Texas. If you purchased or otherwise acquired XBiotech securities between April 15, 2015 and November 23, 2015, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; (3) XBiotech did not adequately sample patients to accommodate data loss; and (4) as a result of not properly sampling patients, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome.
If you suffered a loss in XBiotech you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 



